RxDoctor Payments Data

Sarah Wells, MD

Internal Medicine · Simpsonville, SCNPI 1124467923

Payments from drug & device makers

$1,289in general payments, 2019–2025

Across 46 payments — averaging $28.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$267
  • Lilly USA, LLC$233
  • GSK$133
  • Biohaven Pharmaceutical Holding Company Ltd.$121
  • Novo Nordisk$118
  • AstraZeneca$85
  • plus $332 from 12 others

What the payments were for

  • Food & beverage$1,289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,289 in reported general payments places this provider in the 70th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$36,316
Medicare patients
70
Services billed
702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$33,400
JardianceEmpagliflozin30$19,036
MounjaroTirzepatide17$17,689
TrulicityDulaglutide13$15,841
EliquisApixaban17$13,091
XareltoRivaroxaban14$10,641
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,025
FarxigaDapagliflozin Propanediol12$7,102
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,566
Rosuvastatin Calcium84$1,247
Duloxetine Hcl73$1,134
Gabapentin54$1,125
SynthroidLevothyroxine Sodium11$1,004
Venlafaxine Hcl ErVenlafaxine Hcl37$906
Pantoprazole Sodium77$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$233$33,53030 claims
Novo NordiskOzempic$118$33,40029 claims
PfizerEliquis$27$13,09117 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$46$10,02512 claims
AstraZenecaFarxiga$85$7,10212 claims
AbbVieSynthroid$267$1,00411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Simpsonville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →